No genetic cause for all types of cancer has been identified. Most cases of cancer occur in the absence of a significant family history and are not inherited. In these families, the mutations that cause the cancer occur only in the tumor itself and are acquired after birth. However, about 5-10% of cancers are considered hereditary, and several genetic changes or mutations can be passed from parent to child and increase a person's risk of developing the disease. The mutated genes are also known as "cancer susceptibility genes". Examples of hereditary cancer syndromes are hereditary breast and ovarian cancer syndrome, Li-Fraumeni syndrome, Cowden syndrome, and Lynch syndrome, etc.
We offer the hereditary cancer panel to detect genetic mutations, covering 37 genes associated with cancer. Here, CD Genomics offers an OncoRisk panel for a comprehensive analysis of oncogenes. The panel can analyze 31 oncogenes associated with inherited cancer, which are precisely selected from contract research organizations and numerous research studies.
|OncoRisk Panel||APC ATM BARD1 BLM BMPR1A BRCA1 BRCA2 BRIP1 CDH1 CDK4 CDKN2A CHEK2 EPCAM MLH1 MRE11A MSH2 MSH6 MUTYH NBN PALB2 PMS2 PRSS1 PTEN RAD50 RAD51C RAD51 DSLX4 SMAD4 STK11 TP53 VHL|
Features of our OncoRisk panel
Target Enrichment Method: Hybridization.
Library Preparation Options: All the necessary components for routine library preparation could be involved in our package, such as all-in-one beads/polymerase package option for convenience and efficiency.
Specimen: Blood (> 50 ng of fragmented DNA), FFPE sample.
Market-leading Sensitivity and Specificity: All types of mutations with over 95% sensitivity at 5% VAF, and 99.9% and 99.5% specificity for SNV and Indel, respectively.
Sequencing Platforms: All kinds of Sequencing devices, including Illumina, MGI, PacBio and Nanopore Sequencing platforms.
Gene panel workflow
CD Genomics provides accurate and cost-effective panel sequencing and bioinformatics analysis of 31 oncogenes associated with inherited cancer. Our dedicated team of experts performs quality management, following every procedure to ensure confident and unbiased results. The general workflow for OncoRisk panel is outlined below.
Our OncoRisk panel data may contribute to the development of the era of personalized medicine, specific treatment for each disease-causing mutation in hereditary cancer susceptibility genes, and rational prevention strategies. We look forward to working with you on your innovative discoveries, so please do not hesitate to contact us.